Kroll Bond Rating Agency (KBRA) is pleased to announce the assignment of preliminary ratings to 36 classes of BANK 2021-BNK31, a $905.2 million CMBS conduit transaction collateralized by 61 commercial mortgage loans secured by 126 properties.

The collateral properties are located throughout 30 MSAs, the largest three of which are New York (20.3%), Sacramento (9.9%), and Miami (8.8%). The pool has exposure to all of the major property types, except for lodging, with four types representing more than 10.0% of the pool balance: office (33.9%), retail (25.6%), self-storage (16.4%), and mixed-use (11.6%). The loans have principal balances ranging from $1.0 million to $90.0 million for the largest loan in the pool, McClellan Park (9.9%), which is secured by a 6.9 million sf mixed-use business park located in McClellan, California. The five largest loans also include Miami Design District (2nd largest, 8.8%), 605 Third Avenue (3rd largest, 8.8%), ExchangeRight Net Leased Portfolio #42 (4th largest, 4.5%, 14 properties) and 250 West 57th Street (5^th largest, 4.2%), and represent 36.3% of the initial pool balance, while the top 10 loans represent 55.4%.

KBRAs analysis of the transaction incorporated our multi-borrower rating process that begins with our analysts’ evaluation of the underlying collateral properties’ financial and operating performance, which determine KBRAs estimate of sustainable net cash flow (KNCF) and KBRA value using our U.S. CMBS Property Evaluation Methodology. On an aggregate basis, KNCF was 9.5% less than the issuer cash flow. KBRA capitalization rates were applied to each assets KNCF to derive values that were, on an aggregate basis, 44.1% less than third party appraisal values. The pool has an in-trust KLTV of 94.6% and an all-in KLTV of 103.5%. The model deploys rent and occupancy stresses, probability of default regressions, and loss given default calculations to determine losses for each collateral loan that are then used to assign our credit ratings.

Click here to view the report. To access ratings and relevant documents, click here.

Related Publications

• BANK 2021-BNK31 KBRA Conduit KCAT
• U.S. CMBS Multi-Borrower Rating Methodology
• U.S. CMBS Property Evaluation Methodology
• Methodology for Rating Interest-Only Certificates in CMBS Transactions
• Global Structured Finance Counterparty Methodology

Disclosures

Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above.

A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here.

Information on the meaning of each rating category can be located here.

Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com.

About KBRA

Kroll Bond Rating Agency, LLC (KBRA) is a full-service credit rating agency registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority pursuant to the Temporary Registration Regime. In addition, KBRA is designated as a designated rating organization by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized by the National Association of Insurance Commissioners as a Credit Rating Provider.

Analytical Contacts

Caitlin Parrella, CFA, Associate Director (Lead Analyst)

+1 (646) 731-3310

[email protected]

James Wang, Senior Director

+1 (646) 731-2450

[email protected]

Dayna Carley, Senior Director

+1 (646) 731-2391

[email protected]

Nitin Bhasin, CFA, Senior Managing Director (Rating Committee Chair)

+1 (646) 731-23334

[email protected]

Business Development Contact

Michele Patterson, Managing Director

+1 (646) 731-2397

[email protected]

Domain Capital Group, LLC, a comprehensive private investment management services firm, today announced its subsidiary, Domain Timber Advisors, closed 78 land sales last year, surpassing its 50 total transactions in 2019.

The sales ranged from two to 10,700 acres, with an average of 470 acres. Of the more than 36,000 acres sold in 2020, most occurred in the Southeast while many others were completed in the Northeast, Pacific Northwest and other U.S. timberland regions. Domain Timber has an additional 35 transactions, totaling 16,500 acres of timberland and environmental assets, under agreement for sale.

Our record setting year was partly driven by individuals who wanted to purchase small, rural tracts outside of large cities for varying pandemic-related reasons, said Joe Sanderson, managing director of natural resources at Domain Timber Advisors, LLC, an SEC-registered investment advisor. Due to COVID, there was a considerable increase in outdoor recreational activities, which helped further boost sales. Purchasing interest remains strong for these types of properties and we expect the trend to continue through the first half of this year.

In 2020, buyers also included adjacent landowners, those interested in longer-term timber management and others looking to build homes or subdivisions. In many instances, purchasers sought a mixture of property uses, including recreation and timber management. These properties are historically well-managed forestlands that have been thoughtfully maintained to accommodate multiple uses.

About Domain Capital Group:

Atlanta-based Domain Capital Group, LLC provides comprehensive private investment management services, through its registered investment advisor subsidiaries, to institutions, public and private pensions, corporations, foundations, endowments and high-net-worth individuals. Domain Capital Groups investment professionals are experienced across a diverse range of asset classes and investment strategies, including real estate, natural resources, media, entertainment, technology and credit and other financial services. As of September 30, 2020, Domain managed approximately $6.1 billion in total assets through its two registered subsidiaries, Domain Capital Advisors, LLC and Domain Timber Advisors, LLC. The assets are comprised of approximately $5.5 billion in real estate, debt, alternative and other assets constituting Regulatory Assets Under Management (RAUM) and another $664 million in non-RAUM real properties. Please refer to each registered investment advisors most recent Form ADV for additional details. For further information about Domain Capital Group, visit domaincapitalgroup.com.

Mike Rieman

Cookerly Public Relations

404-419-9230

[email protected]

Immunicom, Inc., a pioneering global biotechnology company, has been recognized as a Top Ten Most Promising 2020 Biotech Startups by StartUpCity Magazine, Immunicom announced today.

Immunicom, featured on the cover of StartUpCitys December 2020 edition, beat out global competition in the broadly defined biotech category to earn this unique recognition.

StartUpCity considered the technology, market, business model, and leadership of each company in order to select the most promising in the sector.

StartUpCity hailed the potential efficacy and affordability of Immunicoms immuno-oncology therapy, noting the company could transcend healthcare barriers” with its novel technology designed to safely manipulate key immune system components without classic side effects typically associated with other treatments. The magazine took special note of Immunicoms apheresis-based medical device as a platform, recognizing the potential to create a multitude of products” for a variety of diseases with a streamlined path to market compared to drugs and conventional therapies.

StartUpCity contrasted the expected affordability of Immunicoms therapy with the increasing cost of many other emerging therapies.

The increased efficacy of emerging treatments for deadly diseases is truly exciting, Immunicoms Founder and CEO, Amir Jafri, said. Immunicom is on the crest of this exciting wave of increasingly effective treatments for these deadly diseases. I believe StartUpCity chose Immunicom as a one of the most promising˜ biotechs with this in mind.

Jafri also commented on the thoroughness of StartUpCitys coverage, which reflected an understanding of the biochemistry as well as the business model.

Immunicoms StartUpCity recognition follows notable progress in the U.S. with recognition as an FDA Breakthrough technology and clinical advancement in Europe. The article can be found at: https://www.startupcity.com/vendor/immunicom-a-single-immunotherapy-solution-to-potentially-treat-all-solidtumor-cancers-without-compromises-cid-579-mid-59.html.

About Immunicom

Immunicom, Inc. creates novel immunotherapies designed to treat a variety of diseases using its breakthrough Immunopheresis„¢ technology platform to improve patient access and affordability. The privately held medical technology company develops innovative, non-pharmaceutical approaches for treating cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicoms revolutionary blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types, including those that have not responded to other treatment strategies, with possibly fewer side effects. Immunicoms lead product, the LW-02 column, has received U.S. FDA Breakthrough Device designation for stage IV metastatic cancer and European regulatory clearance (CE Mark certification) for use in adults with advanced, refractory, triple negative breast cancer (TNBC). Immunopheresis is currently being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Philadelphia, PA, Houston, TX, and Krakow, Poland.

Stephen Prince

[email protected]

657-202-6040